Marker Therapeutics Reports 2023 Net Loss Of $(8.2)M Vs. Net Loss Of $(29.9)M Last Year
Marker Therapeutics Reports 2023 Net Loss Of $(8.2)M Vs. Net Loss Of $(29.9)M Last Year
At December 31, 2023, Marker had cash and cash equivalents of $15.1 million. The Company believes that its existing cash and cash equivalents will fund its operating expenses into the fourth quarter of 2025, inclusive of available drawdowns from grant funds.Reported A Net Loss Of $8.2 Million For The Year Ended December 31, 2023, Compared To A Net Loss Of $29.9 Million
At December 31, 2023, Marker had cash and cash equivalents of $15.1 million. The Company believes that its existing cash and cash equivalents will fund its operating expenses into the fourth quarter of 2025, inclusive of available drawdowns from grant funds.Reported A Net Loss Of $8.2 Million For The Year Ended December 31, 2023, Compared To A Net Loss Of $29.9 Million
截至2023年12月31日，Marker的現金及現金等價物爲1,510萬美元。該公司認爲，其現有的現金和現金等價物將爲2025年第四季度的運營費用提供資金，其中包括從補助基金中提取的可用款項。報告稱，截至2023年12月31日的年度淨虧損爲820萬美元，而淨虧損爲2990萬美元
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧